At the end of June, a teenage girl in Fort Myers, Florida died from complications of COVID-19.
Today reported that when she first started having coronavirus symptoms, her parents, both medical professionals, started giving her at-home treatments. The Food and Drug Administration did not approve these drugs for COVID-19 treatment.
Before her diagnosis, Carsyn Leigh Davis, the 17-year-old, attended an event at church with around 100 kids. The report said that the teen did not wear a face mask, and she was not social distancing.
Three days later on June 13, the 17-year-old had developed sinus pressure, a mild cough, and a headache.
Davis' mother and father thought the teen had developed a sinus infection. Soon after, they gave her azithromycin, an antibiotic that is used to treat bacterial infections. The report stated that the prescription is not an approved treatment for COVID-19.
The medical examiner reported that several days later, Davis' mother said she looked "gray" while sleeping. The mother then tested her daughter's oxygen saturation and got a low reading in the 40s. Readings below 90 are considered unhealthy.
According to the report, the mother hooked her daughter up to her grandfather's oxygen machine, which brought her O2 levels into the 60s. The teen was also given a dose of hydroxychloroquine.
After giving Davis the drug, she tested positive for COVID-19.
Over the next several days, she received "aggressive therapy" and was transferred to Nicklaus Children's Hospital in Miami where she passed away.
In May, a new international poll of thousands of doctors shows that hydroxychloroquine, the drug pushed by President Donald Trump, is the best treatment for coronavirus.
The study, conducted by Sermo, surveyed more than 6,200 doctors from around the world and found that 37 percent called the anti-malaria drug the "most effective therapy" out of 15 options in treating the virus.
The survey also found that 23 percent of healthcare professionals in the U.S. have used the drug, which was sixth-most among significant countries. Spain prescribed it most by far at 72 percent, followed by Italy (49 percent) and Brazil (41 percent).
On June 15, the FDA said that the drug caused too many risks without "enough apparent benefit."